JCC Plus
Cure8 research brief
Why This Matters
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data support that switching does not appear to worsen remission, immunogenicity, or short-term safety.
Who Should Pay Attention
Pediatric patients with IBD and their parents/caregivers, pediatric and adult IBD clinicians, and patients currently receiving infliximab considering or facing a non-medical switch to a biosimilar.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This systematic review and meta-analysis pooled eight studies (508 pediatric patients) comparing switching from originator infliximab to a biosimilar in children and young adults with IBD.
The authors report no meaningful differences in clinical remission at short- or long-term follow-up, similar infliximab trough levels, low rates of newly detectable antidrug antibodies (~2%), and comparable rates of serious adverse events, infusion reactions, and dose escalation.
The review supports that non-medical switching in pediatric IBD appears safe and effective based on the included studies. The analysis used random-effects pooling and reports heterogeneity statistics; treatment persistence after switching was about 85% across studies. The authors registered the review in PROSPERO (CRD420261392963).
The evidence is summarized from the article abstract and pooled results rather than the individual study reports.
If you are a caregiver or clinician considering a switch, this review suggests outcomes are similar after switching, but individual clinical circumstances (disease severity, prior immunogenicity, concomitant immunomodulator use) still matter and should guide decisions.
Discuss monitoring plans (including drug levels and antibodies) with your care team if a switch is planned.
Keep In Mind
Structured content depth: abstract — the brief is grounded in the source-provided abstract and pooled outcomes reported by the authors. The review pools observational studies; results depend on the quality and follow-up of the included studies. This is not a new randomized trial; discuss individual risks and monitoring with your care team.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJCC Plus
AuthorsDouglas Miotto, Maria Clara Abreu Vianna Braga, Sabrine Teixeira Ferraz Grünewald +2 more
InstitutionUniversidade Federal de São Paulo
Study typeReview
Indexed viaOpenAlex
Source typeResearch paper
PublishedOct 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease.
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
DailyMed label update for AVSOLA
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study).
The findings suggest people with IBD on IV infliximab could switch to fixed-dose SC infliximab without losing drug exposure, and many may gain convenience and higher trough drug levels regardless of concomitant...